Renaissance Technologies LLC Purchases 1,337,246 Shares of Lexicon Pharmaceuticals, Inc. $LXRX

Renaissance Technologies LLC boosted its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 508.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 1,600,500 shares of the biopharmaceutical company’s stock after purchasing an additional 1,337,246 shares during the quarter. Renaissance Technologies LLC’s holdings in Lexicon Pharmaceuticals were worth $2,497,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Hudson Bay Capital Management LP purchased a new position in shares of Lexicon Pharmaceuticals in the second quarter valued at about $26,000. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth about $31,000. Leonteq Securities AG purchased a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth about $34,000. EntryPoint Capital LLC bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $39,000. Finally, Virtu Financial LLC bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $42,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on LXRX shares. Zacks Research downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 3rd. Weiss Ratings upgraded shares of Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Citigroup boosted their target price on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $4.55.

Key Headlines Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Lexicon completed enrollment in the pivotal Phase 3 SONATA-HCM study of sotagliflozin for hypertrophic cardiomyopathy, exceeding its 500-patient enrollment target. Top-line results remain expected in the first quarter of 2027, providing a potentially significant future catalyst. Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
• Positive Sentiment: The company said its activities to resubmit the ZYNQUISTA NDA for glycemic control in adults with type 1 diabetes are nearing completion, with resubmission anticipated in the fourth quarter of 2026. Phase 1 development of obesity candidate LX9851 is also continuing through partner Novo Nordisk, and Lexicon could receive an additional $10 million milestone payment as early as later this year. Lexicon Pharmaceuticals Q2 2026 Earnings Call Transcript
• Positive Sentiment: Lexicon reported $190.6 million in cash and investments at June 30, supported by $96.2 million in stock-sale proceeds, giving it additional resources to fund clinical development. A Hercules Capital facility also provides up to $100 million in potential financing, subject to conditions.
• Neutral Sentiment: Management emphasized disciplined capital allocation and early commercial planning for its late-stage pipeline. However, the principal value drivers remain dependent on successful clinical results and regulatory approval.
• Negative Sentiment: Second-quarter revenue fell to approximately $0.7 million from $28.9 million a year earlier because the prior-year period included substantial Novo Nordisk licensing revenue. The company posted a net loss of roughly $31.8 million, or $0.07 per share, versus net income of $3.3 million in the prior-year quarter. Revenue also came in below analyst expectations, while research and development spending rose to $17.4 million as SONATA-HCM costs increased. Lexicon Pharmaceuticals Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals Stock Performance

NASDAQ:LXRX opened at $2.47 on Monday. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -16.47 and a beta of 1.08. Lexicon Pharmaceuticals, Inc. has a 1 year low of $1.02 and a 1 year high of $2.68. The stock’s 50 day simple moving average is $2.20 and its two-hundred day simple moving average is $1.86. The company has a debt-to-equity ratio of 0.29, a current ratio of 13.37 and a quick ratio of 13.29.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%. The firm had revenue of $0.69 million for the quarter, compared to the consensus estimate of $3.99 million. As a group, equities analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.17 earnings per share for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.